Skip to main content
PMC home page
Archives of Disease in Childhood logoLink to Archives of Disease in Childhood
. 1998 Mar;78(3):207–209. doi: 10.1136/adc.78.3.207

Treatment of hyperthyroidism in young people

T CHEETHAM 1, I HUGHES 1, N BARNES 1, E WRAIGHT 1
PMCID: PMC1717503  PMID: 9613348

Full Text

The Full Text of this article is available as a PDF (86.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Babcock M., de Silva D., Oaks R., Davis-Kaplan S., Jiralerspong S., Montermini L., Pandolfo M., Kaplan J. Regulation of mitochondrial iron accumulation by Yfh1p, a putative homolog of frataxin. Science. 1997 Jun 13;276(5319):1709–1712. doi: 10.1126/science.276.5319.1709. [DOI] [PubMed] [Google Scholar]
  2. Barnes N. D. Effects of external irradiation on the thyroid gland in childhood. Horm Res. 1988;30(2-3):84–89. doi: 10.1159/000181034. [DOI] [PubMed] [Google Scholar]
  3. Campuzano V., Montermini L., Moltò M. D., Pianese L., Cossée M., Cavalcanti F., Monros E., Rodius F., Duclos F., Monticelli A. Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion. Science. 1996 Mar 8;271(5254):1423–1427. doi: 10.1126/science.271.5254.1423. [DOI] [PubMed] [Google Scholar]
  4. Carvajal J. J., Pook M. A., dos Santos M., Doudney K., Hillermann R., Minogue S., Williamson R., Hsuan J. J., Chamberlain S. The Friedreich's ataxia gene encodes a novel phosphatidylinositol-4- phosphate 5-kinase. Nat Genet. 1996 Oct;14(2):157–162. doi: 10.1038/ng1096-157. [DOI] [PubMed] [Google Scholar]
  5. Chamberlain S., Shaw J., Rowland A., Wallis J., South S., Nakamura Y., von Gabain A., Farrall M., Williamson R. Mapping of mutation causing Friedreich's ataxia to human chromosome 9. Nature. 1988 Jul 21;334(6179):248–250. doi: 10.1038/334248a0. [DOI] [PubMed] [Google Scholar]
  6. Cooper D. S., Goldminz D., Levin A. A., Ladenson P. W., Daniels G. H., Molitch M. E., Ridgway E. C. Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose. Ann Intern Med. 1983 Jan;98(1):26–29. doi: 10.7326/0003-4819-98-1-26. [DOI] [PubMed] [Google Scholar]
  7. DeGroot L. J., Gorman C. A., Pinchera A., Bartalena L., Marcocci C., Wiersinga W. M., Prummel M. F., Wartofsky L., Marocci C [corrected to Marcocci C. ]. Therapeutic controversies. Retro-orbital radiation and radioactive iodide ablation of the thyroid may be good for Graves' ophthalmopathy. J Clin Endocrinol Metab. 1995 Feb;80(2):339–340. doi: 10.1210/jcem.80.2.7677823. [DOI] [PubMed] [Google Scholar]
  8. Dobyns B. M., Sheline G. E., Workman J. B., Tompkins E. A., McConahey W. M., Becker D. V. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab. 1974 Jun;38(6):976–998. doi: 10.1210/jcem-38-6-976. [DOI] [PubMed] [Google Scholar]
  9. Dürr A., Cossee M., Agid Y., Campuzano V., Mignard C., Penet C., Mandel J. L., Brice A., Koenig M. Clinical and genetic abnormalities in patients with Friedreich's ataxia. N Engl J Med. 1996 Oct 17;335(16):1169–1175. doi: 10.1056/NEJM199610173351601. [DOI] [PubMed] [Google Scholar]
  10. Filla A., De Michele G., Cavalcanti F., Pianese L., Monticelli A., Campanella G., Cocozza S. The relationship between trinucleotide (GAA) repeat length and clinical features in Friedreich ataxia. Am J Hum Genet. 1996 Sep;59(3):554–560. [PMC free article] [PubMed] [Google Scholar]
  11. Franklyn J. A., Daykin J., Drolc Z., Farmer M., Sheppard M. C. Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) 1991 Jan;34(1):71–76. doi: 10.1111/j.1365-2265.1991.tb01738.x. [DOI] [PubMed] [Google Scholar]
  12. Freitas J. E., Swanson D. P., Gross M. D., Sisson J. C. Iodine-131: optimal therapy for hyperthyroidism in children and adolescents? J Nucl Med. 1979 Aug;20(8):847–850. [PubMed] [Google Scholar]
  13. Gibson T. J., Koonin E. V., Musco G., Pastore A., Bork P. Friedreich's ataxia protein: phylogenetic evidence for mitochondrial dysfunction. Trends Neurosci. 1996 Nov;19(11):465–468. doi: 10.1016/S0166-2236(96)20054-2. [DOI] [PubMed] [Google Scholar]
  14. Hall P., Boice J. D., Jr, Berg G., Bjelkengren G., Ericsson U. B., Hallquist A., Lidberg M., Lundell G., Mattsson A., Tennvall J. Leukaemia incidence after iodine-131 exposure. Lancet. 1992 Jul 4;340(8810):1–4. doi: 10.1016/0140-6736(92)92421-b. [DOI] [PubMed] [Google Scholar]
  15. Hamburger J. I. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab. 1985 May;60(5):1019–1024. doi: 10.1210/jcem-60-5-1019. [DOI] [PubMed] [Google Scholar]
  16. Hardisty C. A., Jones S. J., Hedley A. J., Munro D. S., Bewsher P. D., Weir R. D. Clinical outcome and costs of care in radioiodine treatment of hyperthyroidism. J R Coll Physicians Lond. 1990 Jan;24(1):36–42. [PMC free article] [PubMed] [Google Scholar]
  17. Hashizume K., Ichikawa K., Sakurai A., Suzuki S., Takeda T., Kobayashi M., Miyamoto T., Arai M., Nagasawa T. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism. N Engl J Med. 1991 Apr 4;324(14):947–953. doi: 10.1056/NEJM199104043241403. [DOI] [PubMed] [Google Scholar]
  18. Holm L. E., Hall P., Wiklund K., Lundell G., Berg G., Bjelkengren G., Cederquist E., Ericsson U. B., Hallquist A., Larsson L. G. Cancer risk after iodine-131 therapy for hyperthyroidism. J Natl Cancer Inst. 1991 Aug 7;83(15):1072–1077. doi: 10.1093/jnci/83.15.1072. [DOI] [PubMed] [Google Scholar]
  19. Kendall-Taylor P., Keir M. J., Ross W. M. Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J (Clin Res Ed) 1984 Aug 11;289(6441):361–363. doi: 10.1136/bmj.289.6441.361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Lazarus J. H. Guidelines for the use of radioiodine in the management of hyperthyroidism: a summary. Prepared by the Radioiodine Audit Subcommittee of the Royal College of Physicians Committee on Diabetes and Endocrinology, and the Research Unit of the Royal College of Physicians. J R Coll Physicians Lond. 1995 Nov-Dec;29(6):464–469. [PMC free article] [PubMed] [Google Scholar]
  21. Lippe B. M., Landaw E. M., Kaplan S. A. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab. 1987 Jun;64(6):1241–1245. doi: 10.1210/jcem-64-6-1241. [DOI] [PubMed] [Google Scholar]
  22. McIver B., Rae P., Beckett G., Wilkinson E., Gold A., Toft A. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med. 1996 Jan 25;334(4):220–224. doi: 10.1056/NEJM199601253340403. [DOI] [PubMed] [Google Scholar]
  23. Miccoli P., Vitti P., Rago T., Iacconi P., Bartalena L., Bogazzi F., Fiore E., Valeriano R., Chiovato L., Rocchi R. Surgical treatment of Graves' disease: subtotal or total thyroidectomy? Surgery. 1996 Dec;120(6):1020–1025. doi: 10.1016/s0039-6060(96)80049-3. [DOI] [PubMed] [Google Scholar]
  24. Nikiforov Y., Gnepp D. R., Fagin J. A. Thyroid lesions in children and adolescents after the Chernobyl disaster: implications for the study of radiation tumorigenesis. J Clin Endocrinol Metab. 1996 Jan;81(1):9–14. doi: 10.1210/jcem.81.1.8550800. [DOI] [PubMed] [Google Scholar]
  25. Perrild H., Grüters-Kieslich A., Feldt-Rasmussen U., Grant D., Martino E., Kayser L., Delange F. Diagnosis and treatment of thyrotoxicosis in childhood. A European questionnaire study. Eur J Endocrinol. 1994 Nov;131(5):467–473. doi: 10.1530/eje.0.1310467. [DOI] [PubMed] [Google Scholar]
  26. Rudberg C., Johansson H., Akerström G., Tuvemo T., Karlsson F. A. Graves' disease in children and adolescents. Late results of surgical treatment. Eur J Endocrinol. 1996 Jun;134(6):710–715. doi: 10.1530/eje.0.1340710. [DOI] [PubMed] [Google Scholar]
  27. Safa A. M., Schumacher O. P., Rodriguez-Antunez A. Long-term follow-up results in children and adolescents treated with radioactive iodine (131I) for hyperthyroidism. N Engl J Med. 1975 Jan 23;292(4):167–171. doi: 10.1056/NEJM197501232920401. [DOI] [PubMed] [Google Scholar]
  28. Sarkar S. D., Beierwaltes W. H., Gill S. P., Cowley B. J. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med. 1976 Jun;17(6):460–464. [PubMed] [Google Scholar]
  29. Söreide J. A., van Heerden J. A., Lo C. Y., Grant C. S., Zimmerman D., Ilstrup D. M. Surgical treatment of Graves' disease in patients younger than 18 years. World J Surg. 1996 Sep;20(7):794–800. doi: 10.1007/s002689900121. [DOI] [PubMed] [Google Scholar]
  30. Tallstedt L., Lundell G., Tørring O., Wallin G., Ljunggren J. G., Blomgren H., Taube A. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med. 1992 Jun 25;326(26):1733–1738. doi: 10.1056/NEJM199206253262603. [DOI] [PubMed] [Google Scholar]
  31. Tamai H., Hayaki I., Kawai K., Komaki G., Matsubayashi S., Kuma K., Kumagai L. F., Nagataki S. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients. J Clin Endocrinol Metab. 1995 May;80(5):1481–1484. doi: 10.1210/jcem.80.5.7744989. [DOI] [PubMed] [Google Scholar]
  32. Weetman A. P. How antithyroid drugs work in Graves' disease. Clin Endocrinol (Oxf) 1992 Oct;37(4):317–318. doi: 10.1111/j.1365-2265.1992.tb02330.x. [DOI] [PubMed] [Google Scholar]
  33. Weetman A. P., Pickerill A. P., Watson P., Chatterjee V. K., Edwards O. M. Treatment of Graves' disease with the block-replace regimen of antithyroid drugs: the effect of treatment duration and immunogenetic susceptibility on relapse. Q J Med. 1994 Jun;87(6):337–341. [PubMed] [Google Scholar]
  34. Williams D. Thyroid cancer and the Chernobyl accident. J Clin Endocrinol Metab. 1996 Jan;81(1):6–8. doi: 10.1210/jcem.81.1.8550795. [DOI] [PubMed] [Google Scholar]
  35. Williams K. V., Nayak S., Becker D., Reyes J., Burmeister L. A. Fifty years of experience with propylthiouracil-associated hepatotoxicity: what have we learned? J Clin Endocrinol Metab. 1997 Jun;82(6):1727–1733. doi: 10.1210/jcem.82.6.4011. [DOI] [PubMed] [Google Scholar]
  36. Winsa B., Dahlberg A., Jansson R., Agren H., Karlsson F. A. Factors influencing the outcome of thyrostatic drug therapy in Graves' disease. Acta Endocrinol (Copenh) 1990 Jun;122(6):722–728. doi: 10.1530/acta.0.1220722. [DOI] [PubMed] [Google Scholar]

Articles from Archives of Disease in Childhood are provided here courtesy of BMJ Publishing Group

RESOURCES